VALNEVA SE (VLA.PA)
FR0004056851 - Common Stock
We assign a fundamental rating of 3 out of 10 to VLA. VLA was compared to 76 industry peers in the Biotechnology industry. VLA has a bad profitability rating. Also its financial health evaluation is rather negative. VLA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VLA had negative earnings in the past year.
VLA had a negative operating cash flow in the past year.
In the past 5 years VLA always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: VLA reported negative operating cash flow in multiple years.
1.2 Ratios
VLA's Return On Assets of -1.66% is fine compared to the rest of the industry. VLA outperforms 77.46% of its industry peers.
VLA has a better Return On Equity (-4.64%) than 74.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.66% | ||
| ROE | -4.64% | ||
| ROIC | N/A |
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 38.72%, VLA perfoms like the industry average, outperforming 52.11% of the companies in the same industry.
VLA's Gross Margin has declined in the last couple of years.
VLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
2. Health
2.1 Basic Checks
VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VLA has more shares outstanding
Compared to 5 years ago, VLA has more shares outstanding
VLA has a worse debt/assets ratio than last year.
2.2 Solvency
VLA has an Altman-Z score of -0.97. This is a bad value and indicates that VLA is not financially healthy and even has some risk of bankruptcy.
VLA has a Altman-Z score of -0.97. This is comparable to the rest of the industry: VLA outperforms 43.66% of its industry peers.
A Debt/Equity ratio of 1.13 is on the high side and indicates that VLA has dependencies on debt financing.
VLA has a Debt to Equity ratio of 1.13. This is in the lower half of the industry: VLA underperforms 63.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.13 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.97 |
ROIC/WACCN/A
WACC8.28%
2.3 Liquidity
A Current Ratio of 2.63 indicates that VLA has no problem at all paying its short term obligations.
VLA's Current ratio of 2.63 is fine compared to the rest of the industry. VLA outperforms 60.56% of its industry peers.
A Quick Ratio of 2.15 indicates that VLA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.15, VLA is in line with its industry, outperforming 52.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.63 | ||
| Quick Ratio | 2.15 |
3. Growth
3.1 Past
The earnings per share for VLA have decreased strongly by -355.56% in the last year.
Looking at the last year, VLA shows a very negative growth in Revenue. The Revenue has decreased by -58.35% in the last year.
The Revenue has been growing slightly by 6.34% on average over the past years.
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-58.35%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%-5.41%
3.2 Future
Based on estimates for the next years, VLA will show a very strong growth in Earnings Per Share. The EPS will grow by 35.23% on average per year.
Based on estimates for the next years, VLA will show a very strong growth in Revenue. The Revenue will grow by 22.69% on average per year.
EPS Next Y102.42%
EPS Next 2Y22.46%
EPS Next 3Y21.1%
EPS Next 5Y35.23%
Revenue Next Year11.96%
Revenue Next 2Y14.34%
Revenue Next 3Y19.95%
Revenue Next 5Y22.69%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VLA's earnings are expected to grow with 21.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.46%
EPS Next 3Y21.1%
5. Dividend
5.1 Amount
VLA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VALNEVA SE
EPA:VLA (9/6/2024, 7:00:00 PM)
3.08
-0.05 (-1.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap214.30M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.66% | ||
| ROE | -4.64% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.13 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.63 | ||
| Quick Ratio | 2.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y102.42%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-58.35%
Revenue growth 3Y11.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y